The Complying Product Amendment Rules

Nursing-home type patient contribution rates have been updated to reflect the indexation applied to the Adult Pension Basic Rate and Maximum Daily Rate of Rental Assistance.

The amendments update the patient contribution rates for nursing-home type patients in Queensland, New South Wales, South Australia, Northern Territory, Tasmania, and Western Australia; and increased the private hospitals nationally.

State/Territory

Contribution Rates

Queensland

from $54.75 to $55.80

New South Wales

from $54.75 to $55.80

Northern Territory

from $52.05 to $55.80

South Australia

from $54.75 to $55.80

Tasmania

from $54.75 to $55.80

Western Australia

from $54.75 to $55.80

Private hospitals nationally

from $54.75 to $55.80

The existing rates for other states and territories remain in force and are as follows:

State/Territory

Contribution Rates

Australian Capital Territory

$53.55

Victoria

$54.75

The Benefit Requirements Amendment Rules

Nursing-Home Type Patients - Schedule 4

Nursing-home type patient minimum benefits have been updated to reflect the indexation applied to the Adult Pension Basic Rate and Maximum Daily Rate of Rental Assistance.

The amendments increase the minimum benefits payable for privately insured nursing-home type patients at public hospitals in New South Wales, Tasmania and Northern Territory, and decrease the minimum benefits payable at private hospitals nationally. The changes are as follows:

State/Territory

Minimum benefit per night

New South Wales

from $111.70 to $114.05

Tasmania

from $131.40 to $133.90

Northern Territory

From $77.47 to $83.10

Private hospitals nationally

from $56.35 to $55.30

The existing rates for other states and territories remain in force and are as follows:

Item 1 amends Schedule 3, Part 3 Type C procedures, Clause 8 Interpretation, Category 3 Therapeutic procedures, T11 of the Principal Rules by inserting 1 MBS item (18377). This MBS item relates to therapeutic procedures which are not usually performed in hospital. However, it is recognised that this item may be performed, in rare cases, in isolation in hospital if determined by the treating medical practitioner.

MBS item 18377 commenced on 1 March 2014 under a remake of the Health Insurance (General Medical Services Table) Regulations. MBS item 18377 is a new item to make benefits available for the treatment of chronic migraine with the injection of botulinum toxin type A for patients 18 years or older who have experienced an inadequate response to at least 3 prophylactic migraine medications before commencement, and the requirements relating to botulinum toxin type A under the Pharmaceutical Benefits Scheme are complied with.